SEHK:801

Stock Analysis Report

Golden Meditech Holdings

Executive Summary

Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare company in the People’s Republic of China.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Golden Meditech Holdings has significant price volatility in the past 3 months.
  • Golden Meditech Holdings is not covered by any analysts.

Share Price & News

How has Golden Meditech Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.4%

SEHK:801

6.4%

HK Healthcare

2.2%

HK Market


1 Year Return

-3.4%

SEHK:801

-23.1%

HK Healthcare

-11.1%

HK Market

801 outperformed the Healthcare industry which returned -22.7% over the past year.

801 outperformed the Market in Hong Kong which returned -12.3% over the past year.


Share holder returns

801IndustryMarket
7 Day2.4%6.4%2.2%
30 Day-11.5%-4.2%-7.3%
90 Day13.3%-2.0%-4.8%
1 Year-3.4%-3.4%-21.5%-23.1%-7.9%-11.1%
3 Year9.3%-15.0%-26.0%-30.5%15.5%4.1%
5 Year-16.9%-37.5%-14.5%-16.7%10.0%-8.2%

Price Volatility Vs. Market

How volatile is Golden Meditech Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Golden Meditech Holdings undervalued based on future cash flows and its price relative to the stock market?

0.57x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Golden Meditech Holdings to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Golden Meditech Holdings to establish if it is available at substantial discount.


Price Based on Earnings

Golden Meditech Holdings is loss making, we can't compare its value to the HK Healthcare industry average.

Golden Meditech Holdings is loss making, we can't compare the value of its earnings to the Hong Kong market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Golden Meditech Holdings, we can't assess if its growth is good value.


Price Based on Value of Assets

Golden Meditech Holdings is good value based on assets compared to the HK Healthcare industry average.


Next Steps

Future Growth

How is Golden Meditech Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Golden Meditech Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Golden Meditech Holdings performed over the past 5 years?

-1.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Golden Meditech Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Golden Meditech Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Golden Meditech Holdings's 1-year growth to the HK Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Golden Meditech Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Golden Meditech Holdings has efficiently used its assets last year compared to the HK Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Golden Meditech Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Golden Meditech Holdings's financial position?


Financial Position Analysis

Golden Meditech Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Golden Meditech Holdings's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Golden Meditech Holdings's level of debt (20.2%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (27.7% vs 20.2% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Golden Meditech Holdings has sufficient cash runway for more than 3 years based on current free cash flow.

Golden Meditech Holdings has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 45.5% each year.


Next Steps

Dividend

What is Golden Meditech Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Golden Meditech Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Golden Meditech Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Golden Meditech Holdings has not reported any payouts.

Unable to verify if Golden Meditech Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Golden Meditech Holdings has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Golden Meditech Holdings's salary, the management and board of directors tenure and is there insider trading?

0.3yrs

Average board tenure


CEO

Kim Leong (49yo)

0.3yrs

Tenure

0

Mr. Kim Chuan Leong serves as Chief Executive Officer, Compliance Officer and Executive Director of Golden Meditech Holdings Limited since May 24, 2019. He serves as Deputy Chief Financial Officer at Golde ...


Board Age and Tenure

0.3yrs

Average Tenure

44.5yo

Average Age

The average tenure for the Golden Meditech Holdings board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellHK$886,81926 Apr 19
Atlantis Investment Management (Ireland) Limited
EntityCompany
Shares1,112,000
Max PriceHK$0.80

Ownership Breakdown


Management Team

  • Dao Pei Lu (87yo)

    President of Shanghai Dao Pei Hospital

    • Tenure: 0.0yrs
  • Zu Qin Lai (80yo)

    Chief Scientist of Qijieyuan and Inventor of TangHerb

    • Tenure: 0.0yrs
  • Bao Shao (53yo)

    Chief Executive Officer of the Chinese Herbal Medicine Operation

    • Tenure: 0.0yrs
  • Jian Zhong Jing (65yo)

    VP & Chief Representative of Shanghai Office

    • Tenure: 0.0yrs
  • Wei Ding (70yo)

    Chief Executive Officer of GM Medicare Management (China) Company Limited

    • Tenure: 0.0yrs
  • Wen Feng (51yo)

    Chairman of the Board

    • Tenure: 0.3yrs
    • Compensation: HK$2.47m
  • Fan Huang (45yo)

    Chief Executive Officer of Medical Devices Operation

    • Tenure: 0.0yrs
  • Kim Leong (49yo)

    CEO, Deputy CFO

    • Tenure: 0.3yrs
  • Joanna Rui

    Investor Relations Manager

    • Tenure: 0.0yrs
  • Cheuk Man Lam

    Company Secretary

    • Tenure: 0.3yrs

Board Members

  • Xue Tao Pei

    Member of Technology Development Advisory Board

    • Tenure: 0.0yrs
  • Ming Tian

    Member of Technology Development Advisory Board

    • Tenure: 0.0yrs
  • Bao Guo Wang

    Member of Technology Development Advisory Board

    • Tenure: 0.0yrs
  • Ming Li Zhang

    Chairman of Technology Development Advisory Board

    • Tenure: 0.0yrs
  • Albert Chen (43yo)

    CFO & Executive Director of China Cord Blood Corporation

    • Tenure: 0.0yrs
  • Wen Feng (51yo)

    Chairman of the Board

    • Tenure: 0.3yrs
    • Compensation: HK$2.47m
  • Yue Gao (46yo)

    Independent Non Executive Director

    • Tenure: 4.8yrs
    • Compensation: HK$460.00k
  • Daniel Foa (42yo)

    Independent Non-Executive Director

    • Tenure: 4.5yrs
    • Compensation: HK$600.00k
  • Kim Leong (49yo)

    CEO, Deputy CFO

    • Tenure: 0.3yrs
  • Poon Hang (41yo)

    Independent Non-Executive Director

    • Tenure: 0.3yrs

Company Information

Golden Meditech Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Golden Meditech Holdings Limited
  • Ticker: 801
  • Exchange: SEHK
  • Founded: 2001
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: HK$2.479b
  • Shares outstanding: 2.92b
  • Website: https://www.goldenmeditech.com

Number of Employees


Location

  • Golden Meditech Holdings Limited
  • No. 11 Wan Yuan Street
  • Beijing Economic Technological Development Area
  • Beijing
  • 100176
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GMDT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2001
801SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDDec 2001

Biography

Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare company in the People’s Republic of China. It operates in five segments: Medical Devices, Hospital Busi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 12:38
End of Day Share Price2019/08/22 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.